Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
Go back to Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma| Gilead Sciences (NASDAQ: GILD) | Delayed: 158.35 +2.31 (1.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $156.04 | 52 Week High | $108.63 | |||
| Open | $157.62 | 52 Week Low | $71.39 | |||
| Day High | $159.69 | P/E | 87.49 | |||
| Day Low | $157.59 | EPS | $1.81 | |||
| Volume | 3,618,838 | |||||



